Aptevo Therapeutics Inc (NASDAQ:APVO) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price objective of $6.00 for the company and are anticipating that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 193 out of 265 based on the ratings given to its competitors.
Separately, ValuEngine lowered shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 10th.
A number of large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its holdings in Aptevo Therapeutics by 87.2% during the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock valued at $287,000 after buying an additional 31,578 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Aptevo Therapeutics by 8.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after buying an additional 78,109 shares during the last quarter. Virtu Financial LLC bought a new stake in Aptevo Therapeutics during the 4th quarter valued at $690,000. Finally, Victory Capital Management Inc. bought a new stake in Aptevo Therapeutics during the 4th quarter valued at $827,000. Institutional investors own 32.28% of the company’s stock.
Shares of Aptevo Therapeutics (NASDAQ APVO) traded up $0.07 on Friday, hitting $3.08. 140,401 shares of the stock were exchanged, compared to its average volume of 251,907. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.76 and a quick ratio of 7.67. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.85.
Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.14 EPS for the quarter, missing the Zacks’ consensus estimate of $2.25 by ($2.11). Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 28.03%. equities research analysts expect that Aptevo Therapeutics will post 0.43 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/10/zacks-aptevo-therapeutics-inc-apvo-receives-average-rating-of-strong-buy-from-brokerages.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.